HOLD - Do not add, do not trim; wait for confirmed technical signals

• 9.3x forward P/E treats a forecast as a floor when Eliquis faces patent loss starting late 2026 on a roughly twelve billion dollar revenue product
• 153% EPS growth masks depressed Q2 2025 base ($0.64) from acquisition-related charges and tough comparable
• Price action rejecting good news: stock dropped from $68 to $61 over three weeks on rising volume with fourteen consecutive lower highs
• MACD still expanding negative, VWMA falling in lockstep with price signals distribution not pension rebalancing
• Four layers of overhead resistance represent structural momentum shifts: 10 EMA rolled from $67 in 13 sessions, 50 SMA flattened after August, Bollinger Middle at $65.15
• Downside targets identified are 52-55 and then 42, representing 15-30% downside not 5%, with 200 SMA break being a lagging confirmation indicator
• Scale-in proposal lacks momentum confirmation: stock below both 10 EMA and 50 SMA, sitting on lower Bollinger Band ($60.90) with no bottom in place
• Existing technical gates (50 SMA reclaim at $64.14, VWMA reclaim with MACD contraction, retest of $66 breakout) exist to ensure buying strength not weakness

→ vs aggressive: Forward P/E of 9.3x is a forecast not a floor; $6.56 EPS estimate will be cut as Eliquis revenue steps down starting late 2026, similar to BMY's Revlimid erosion

→ vs aggressive: 153% EPS growth is a base effect from depressed Q2 2025, not operating leverage; Q2 2026 is already in the rearview mirror

→ vs aggressive: Distribution signature (heavy volume down day, VWAP declining, MACD with no contracting histogram bars) is not explained away by beta (0.23) being a backward-looking measure

→ vs aggressive: Higher-for-longer macro regime is fully priced in after months; dividend yield premium not a new discovery and would not leave stock at lower Bollinger Band if it were a catalyst

→ vs aggressive: Overhead resistance layers are momentum shifts, not just moving averages; short and medium-term MAs breaking down simultaneously signals structural trend change

→ vs aggressive: Risk-reward understates downside to 15-30% at 52-55 and 42 targets; 200 SMA break is a lagging indicator meaning stock will already be at 53 when confirmed

→ vs aggressive: Scale-in proposal removes all existing technical entry gates and constitutes catching a falling knife rather than disciplined position building

HOLD with small tactical pilot allocation; retain core exposure; stop at $58.23

• 10 EMA rolled over from 67 to 63 in thirteen sessions, 50 SMA broke to downside and flattening
• MACD histogram expanding negative at minus 0.57 with no contracting bar
• Lower Bollinger Band test at $60.91; next support at $58.23; band holding probability ~55-45
• ATR contracting from 1.94 to 1.38 after sharp drop — suggests band-width re-expansion ahead
• 200 SMA structurally intact — longer-term uptrend not broken
• Net Debt/EBITDA deleveraging from 2.49x to 1.82x in 18 months underway
• Revenue grew 7.5% YoY in Q2; FCF $13 billion annualized
• 4% dividend yield with 2x coverage provides income floor
• Forward multiple at historically low levels
• Pilot allocation recommended: half/quarter size of aggressive tranche at $61.15 with stop at $60.50
• Add tranche at $63 area on RSI bullish divergence or MACD histogram contraction if lower band holds
• Partial trim of 25-30% of position appropriate into confirmed $64.14 strength
• Eliquis LOE is known-known overhang capping multiple expansion but not invalidating income/defensive thesis
• Macro (Fed policy 90-96% no-cut) is context, not trade driver

→ vs aggressive: Scaling into a position with rolled-over 10 EMA, broken 50 SMA, and expanding negative MACD at a coin-flip 55-45 setup lacks momentum confirmation and risks immediate stop-out at $58.23

→ vs conservative: Calling a 10% pullback in a 0.23-beta defensive compounder that went from $42 to $68 a regime change is overreach — ATR contraction from 1.94 to 1.38 typically precedes band-width re-expansion, not continued breakdown